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Background Arsenic exposure through drinking water is a serious global health
issue. Observational studies suggest that individuals who metabol-
ize arsenic efficiently are at lower risk for toxicities such as arsen-
ical skin lesions. Using two single nucleotide polymorphisms
(SNPs) in the 10q24.32 region (near AS3MT) that show independent
associations with metabolism efficiency, Mendelian randomization
can be used to assess whether the association between metabolism
efficiency and skin lesions is likely to be causal.
Methods Using data on 2060 arsenic-exposed Bangladeshi individuals, we
estimated associations for two 10q24.32 SNPs with relative concen-
trations of three urinary arsenic species (representing metabolism
efficiency): inorganic arsenic (iAs), monomethylarsonic acid
(MMA) and dimethylarsinic acid (DMA). SNP-based predictions
of iAs%, MMA% and DMA% were tested for association with skin
lesion status among 2483 cases and 2857 controls.
Results Causal odds ratios for skin lesions were 0.90 (95% confidence inter-
val [CI]: 0.87, 0.95), 1.19 (CI: 1.10, 1.28) and 1.23 (CI: 1.12, 1.36)
for a one standard deviation increase in DMA%, MMA% and iAs%,
respectively. We demonstrated genotype-arsenic interaction, with
metabolism-related variants showing stronger associations with
skin lesion risk among individuals with high arsenic exposure (syn-
ergy index: 1.37; CI: 1.11, 1.62).
Conclusions We provide strong evidence for a causal relationship between ar-
senic metabolism efficiency and skin lesion risk. Mendelian ran-
domization can be used to assess the causal role of arsenic
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exposure and metabolism in a wide array of health conditions.
Developing interventions that increase arsenic metabolism effi-
ciency are likely to reduce the impact of arsenic exposure on health.
Keywords Arsenic, arsenic metabolism, Mendelian randomization, gene-envir-
onment interaction, AS3MT
Background
Arsenic exposure through drinking water has been a
serious public health issue in many countries around
the world, including Bangladesh, India, Taiwan,
Mexico, Argentina, Chile and the USA, affecting ap-
proximately 140 million individuals worldwide.1 In
addition to being a known carcinogen with estab-
lished effects on bladder, liver, skin and kidney
cancer risk,2–7 arsenic has been reported to increase
risk for cardiovascular conditions,8 pregnancy compli-
cations,9 neurological conditions10,11 and overall mor-
tality.12,13 In general, these associations are quite clear
at high levels of exposure (4300 mg/l in water) but less
consistent at lower levels of exposure. Skin lesions are
the classical sign of arsenic toxicity, and risk for such
lesions shows a dose-response relationship with ar-
senic exposure.14 Skin lesions are believed to reflect
susceptibility to arsenic-related disease, including
cancer.5
Arsenic (As) consumed in drinking water enters the
blood as inorganic arsenic (iAs): AsV and AsIII. iAs
then undergoes a series of oxidation and methylation
steps to produce monomethylarsonic acid (MMA) and
then dimethylarsinic acid (DMA). These reactions in-
volve S-adenosyl methionine (SAM) as the methyl
donor and are catalyzed by methyltransferase en-
zymes, most notably, arsenite methyltransferase
(AS3MT). These arsenic species (iAs, MMA and
DMA) are excreted in urine and can be measured
and expressed as percentages of total urinary arsenic
(iAs%, MMA% and DMA%). These percentages are
measures of an individual’s capacity to methylate
arsenic, which shows considerable inter-individual
variation.15 Urinary iAs% and MMA% are positively
correlated whereas DMA% shows strong negative cor-
relations with iAs% and MMA%.16–18 Thus, high
DMA% (and low iAs% and MMA%) represent
enhanced methylation capacity whereas high iAs%
and MMA% (and low DMA%) represent low methy-
lation capacity. Increased methylation capacity has
been hypothesized to decrease susceptibility to ar-
senic-related toxicity, presumably due to enhanced
excretion and lower toxicity of DMA relative to iAs
and MMA.15 Several epidemiological studies have re-
ported that increased methylation capacity is inversely
associated with risk for arsenical skin lesions.17–21
In previous work, our group16 and others22,23 have
shown that genetic variation in the 10q24.32 region
(containing AS3MT and other genes) influences
arsenic methylation capacity in Bangladeshi individ-
uals, after adjusting for arsenic exposure. We demon-
strated that multiple single nucleotide polymorphisms
(SNPs) in this region are independently associated
with urinary DMA% and MMA%, with one SNP
showing evidence of association with skin lesion
risk through interaction with arsenic. In this work,
using a larger sample size compared with our prior
study, we are now able to rigorously address the hy-
pothesis that arsenic methylation capacity (measured
as arsenic species percentages) has a causal role in
arsenic toxicity (measured as skin lesions) using a
Mendelian randomization (MR) approach (Figure 1).
MR is a method for assessing the causal effect of a
risk factor on a disease outcome using genetic deter-
minants of the risk factor as instrumental variables
(IVs).24,25 If the IVs are valid, the MR estimate rep-
resents the causal component of the observed associ-




Subjects genotyped for this work were participants in
one of two ongoing studies of arsenic exposure in
Bangladesh: the Health Effects of Arsenic Longitudi-
nal Study (HEALS)26 and the Bangladesh Vitamin E
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Figure 1 A causal diagram representing the relationships
among 10q24.32 genetic variants, arsenic methylation cap-
acity, urinary arsenic metabolites and arsenical skin lesion
risk in an arsenic-exposed population. For simplicity, arsenic
exposure is not shown, but the hypothesized effect of ar-
senic methylation capacity on skin lesions would occur
through an interaction with arsenic exposure
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and Selenium Trial (BEST).27 HEALS is a prospective
investigation of health outcomes associated with ar-
senic exposure through drinking water in a popula-
tion-based cohort of 11 746 adults (age 18–75 years)
in Araihazar, Bangladesh, a rural area east of the cap-
ital city, Dhaka (described in detail in reference 26). A
total of 10 970 wells in the study area were tested for
arsenic, and individuals were assigned an arsenic ex-
posure level based on their reported primary drinking
well. BEST is a 2 2 factorial randomized chemopre-
vention trial evaluating the long-term effects of
vitamin E and selenium supplementation on non-mel-
anoma skin cancer risk among 7000 individuals with
arsenic-related skin lesions living in Araihazar (the
same geographical area as HEALS), Matlab and sur-
rounding areas. BEST uses many of the same study
protocols as does HEALS, in particular those for ex-
posure assessment and biospecimen collection. Addi-
tional details on these studies can be found in the
Supplementary data (available at IJE online).
Eligibility
Participants included in this work are a subset of
HEALS and BEST participants from Araihazar that
were genotyped at 4250 000 SNPs using Illumina’s
HumanCytoSNP-12 v2.1 chips (n¼ 5340). Analyses
of urinary arsenic species were conducted among
2060 genotyped HEALS participants with available
data on DMA%, MMA% and iAs% (measured at base-
line). This sample includes all 1313 individuals
included in our prior study.16 Analyses of skin
lesion status was conducted among 5340 genotyped
individuals (2483 skin lesion cases and 2857 controls)
selected from both studies, including the 2060 HEALS
individuals with metabolite data. This sample includes
all 1085 cases and all 1794 controls included in our
prior study. Skin lesion cases included individuals
with keratosis, melanosis and leukomelanosis. A sum-
mary of the participants included in this study is pro-
vided in Figure 2.
Laboratory methods
DNA extraction and quality control (QC) for HEALS
and BEST blood samples have been described previ-
ously.16 Genotyping was conducted in two batches of
approximately equal size, containing approximately
equal numbers of skin lesion cases and controls.
Samples were genotyped on Illumina HumanCy-
toSNP-12 v2.1 chips (300 000 SNPs). QC was per-
formed using PLINK,28 the details of which are
contained in the Supplementary data at IJE online.
After QC, high-quality genotype data were available
for 5354 individuals and 257 747 SNPs.
In both HEALS and BEST, urinary arsenic was mea-
sured using a graphite furnace atomic absorption
spectrometry method with a very low limit of detec-
tion (1 mg/l) in a single laboratory at Columbia
University.29 For a subset of HEALS participants,
urinary arsenic metabolites (arsenobetaine,
arsenocholine, arsenite, arsenate, MMA and DMA)
were distinguished as described by Ahsan et al.,18
using a high-performance liquid chromatography
method for separation of arsenic metabolites, followed
by detection using inductively coupled plasma-mass
spectrometry with dynamic reaction cell. The total
concentrations of iAs (arsenate and arsenite), MMA
and DMA in urine were expressed as a percentage of
total arsenic, after subtracting asenobetaine and
arsenocholine (i.e. nontoxic organic arsenic from diet-
ary sources). In HEALS, arsenic in drinking water was
measured at baseline using graphite furnace atomic
absorption spectrometry (and inductively coupled
plasma-mass spectrometry for samples with concen-
trations below the limit of detection).
Skin lesion assessment
In both HEALS and BEST, a structured protocol was
used to ascertain skin lesions, implemented by study
physicians who had undergone training for the detec-
tion and diagnosis of skin lesions. The study physician
recorded the presence or absence of melanosis (hyper-
pigmentation), leucomelanosis (hypopigmentation) or
keratosis (a hyperkeratotic thickening of the skin typ-
ically on the palms and soles) and the location of the
lesion.30 For the present case-control analysis, skin
lesion status was defined as any type of skin lesion
detected at either baseline (in HEALS or BEST) or
during follow-up (HEALS).
Statistical methods
Associations between SNPs in the 10q24.32 region
(coded as 0, 1 or 2 minor alleles) and urinary arsenic
species percentages (measured at baseline) were esti-
mated using mixed linear models31 to account for
cryptic relatedness in this population (described in
the Supplementary data available at IJE online).
Logistic regression was used to estimate observational
associations between arsenic species percentages and
skin lesion status using data on 632 cases and 4036
controls with available urinary arsenic species data
(all from HEALS). As previously reported, there is
very little evidence of population structure in our
sample (based on principal components analysis,
after removal of one individual from each related
pair),16 thus no adjustments for principle components
were required. Imputation of unmeasured genotypes
did not produce imputed SNPs that were stronger pre-
dictors of arsenic methylation capacity than our gen-
otyped SNPs, so results for imputed SNPs are not
presented.
We used an MR approach to assess the causal effect
of methylation capacity (measured as urinary arsenic
species percentages) on skin lesion risk using sequen-
tial regressions. In the first-stage mixed linear model
(n¼ 2060), the arsenic methylation capacity variable
was regressed on two genotyped 10q24.32 SNPs
(i.e. the IVs) adjusting for sex, age, smoking, body
mass index and genotyping stage. Each arsenic
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species measure (DMA%, MMA% and iAs%) was used
to represent arsenic methylation capacity in three sep-
arate MR models. rs9527 and rs11191527 were se-
lected as IVs because these SNPs best represent the
two independent association signals in this region for
each metabolite. Using two IVs in the same model
(each coded as 0,1 or 2 risk alleles), rather than a
single IV (such as a weighted SNP allele score),
allowed us to make no assumptions regarding relative
effect sizes of these SNPs, avoiding the loss of power
associated with mis-specifying allele weights.32 In the
second-stage logistic regression (2483 cases and 2857
controls), skin lesion status was regressed on the pre-
dicted values of arsenic metabolites based on the beta
coefficients from the first-stage regression, again ad-
justing for the same covariates as the first stage. Our
recent work has shown that this two-stage procedure
with linear and logistic regression maintains appropri-
ate type I errors rates but may be very slightly biased
towards the null;33 thus, our estimates may be some-
what conservative.
Observational (cross-sectional) association estimates
between each arsenic species measure and skin lesion
risk were estimated using a subset of HEALS partici-
pants with available data on urinary arsenic species
and skin lesion status, many of whom did not have
SNP data (632 skin lesion cases and 4036 controls).
Differences between observational and MR estimates
were tested in Stata using the suest command (seem-
ingly unrelated regression).
Gene-environment interaction analysis was con-
ducted among a set of 493 cases and 2823 controls
(all from HEALS) with prospective data on arsenic
exposure from drinking water (measured prior to ar-
senic mitigation efforts34 using logistic regression
(Figure 2). In logistic regression models, arsenic
exposure was modelled as tertiles and genotypes
were modelled as binary variables indicating minor
allele carriers and non-carriers. Individuals were as-
signed to ‘low’, ‘intermediate’ and ‘high’ methylation
capacity categories based on their genotypes at rs9527
and rs11191527. Additive interaction was estimated in
two ways: the synergy index and relative excess risk
due to interaction (RERI).35,36 Additional details of
SNP-arsenic interaction methods are provided in the
Supplementary data at IJE online.
Results
Associations between SNPs and arsenic
metabolism
Associations between SNPs in the 10q24.32 region and
urinary arsenic species percentages (measured at base-
line) were estimated using data on 2 060 HEALS par-
ticipants, described in Table 1. Consistent with prior
findings,16,22,23 10q24.32 variants showed association
signals for both MMA% and DMA% (P <1010) and
a weaker signal for iAs% (P¼ 5 x 105). For DMA%,
MMA% and iAs%, the SNP showing the smallest P-
value was rs9527 (P¼ 1.1 1011, P¼ 2.5 1011 and
P¼ 5.8 105, respectively). After conditioning on
rs9527, there were strong secondary signals for all
three arsenic species, with rs11191527 best represent-
ing this secondary signal for DMA% (P¼ 8.7 1010),
MMA% (P¼ 2.9 106) and iAs% (P¼ 2.9 106)
(Supplementary Figure 1, available as Supplementary
data at IJE online). After adjusting for these two in-
dependent association signals, no additional evidence
of association was observed for any of the three ar-
senic species (i.e. all P 410-4 for each species across
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Figure 2 A description of the participants included in this study
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signals). For these two SNPs (rs9527 and rs11191527),
which are in mild linkage disequilibrium (D0¼ 0.26;
r2¼ 0.04), the alleles associated with increases in
DMA% are associated with decreases in MMA% and
iAs%, as expected based on correlations among the
metabolite measures (Figure 3). Results remained
the same after exclusion of 68 prevalent skin lesion
cases from the analysis. These results suggest that the
relative concentrations of iAs, MMA and DMA are
influenced by a common set of underlying causal vari-
ants, and that these variants represent an individual’s
capacity to produce DMA, the end product of arsenic
metabolism. We acknowledge the two lead SNPs re-
ported here are not the top SNPs reported in our prior
smaller study. Those SNPs remain strongly associated
with methylation capacity, but based on the larger
sample size used in this work, the previously reported
SNPs no longer have the lowest P-values for the two
signals in this region. The previously reported SNPs
remain adequate tagSNPs for the two association sig-
nals we observe.
Mendelian randomization
The direction of the observational association between
arsenic methylation capacity and skin lesion risk
(Figure 4) is consistent with associations reported in
prior work,17,19–21 including our prior report,18 with
increased methylation capacity (high DMA% and
low MMA% and iAs%) being associated with
decreased skin lesion risk. Our IV SNPs show little
evidence of association with the potential confound-
ing factors shown in Tables 1 and 2, supporting the
validity of these SNPs as IVs that are useful for MR
(Supplementary Table 1, available as Supplementary
data at IJE online). MR analysis indicated that a
causal relationship underlies this association, with
each of the three metabolites producing a causal OR
with P <0.0001 and a direction consistent with the
observational associations (Figure 4). The first-stage
F-statistics from all models were 415, ensuring that
our results are free from appreciable weak-IV
biases.32,37 Results excluding covariates adjustments
were similar to those from adjusted analyses.
10q24.32 is a well-established arsenic metabolism
locus;23 however, in order to ensure that our MR es-
timates were not biased due to the fact that we se-
lected our IV SNPs using a subset of the data we used
for MR, a cross-validation analysis (described in the
Supplementary data at IJE online) was used to con-
firm that this phenomenon did not account for the
MR results. For DMA% and MMA%, this cross-valid-
ation approach produced results very similar to those
obtained in the primary MR analysis (Supplementary
Table 2, available as Supplementary data at IJE
Table 1 Mean urinary arsenic species percentages (reflect-
ing arsenic methylation capacity) for 2060 HEALS partici-
pants with arsenic metabolite data
Characteristic % iAs% MMA% DMA%
Sex
Male 50.4 14.9 15.3 69.8
Female 49.6 15.2 11.6 73.2
Age (yr)
430 26.2 16.1 11.9 71.9
31–39 23.9 15.8 13.1 71.0
40–48 26.4 14.9 13.8 71.2
549 23.5 13.3 15.1 71.7
BMI (kg/m2)
<17.38 25.0 15.4 14.3 70.3
17.38–19.03 25.0 15.3 13.9 70.8
19.04–21.37 25.0 15.1 13.3 71.7
421.37 25.0 14.6 12.3 72.9
Cigarette smoking
Current 34.8 15.0 14.9 70.1
Former 8.5 15.3 12.2 72.4
Never 56.7 13.9 15.4 70.7
Urinary arsenic (mg/g)
<101 25.1 14.0 13.4 72.7
101–185 24.9 14.6 13.0 72.4
186–320 25.0 15.5 13.4 71.1
5321 25.1 16.3 14.0 69.6
Water arsenic(mg/l)
<9.0 25.2 13.9 12.9 73.2
9.0–49.9 24.7 15.0 13.1 71.9
50.0–127.9 25.1 15.4 13.6 70.9
5128 25.0 16.0 14.1 69.9
The participants with metabolite data described in this table are
all HEALS cohort members and are a subset of the larger case-
control sample described in Table 2. Bold numbers represent
P-values <0.05 for global test of association for each character-
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Figure 3 Associations between 10q24.32 SNPs and arsenic
species percentages. Estimates for SNPs were generated in
multivariate linear regression models that included sex, age
categories and both SNPs (n¼ 2060). The observed allele
frequencies for the low-efficiency alleles of rs9527 (A) and
rs11191527 (G) are 0.08 and 0.84, respectively
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online). The effects of our two SNPs on iAs% were not
strong enough for cross-validation analyses to be con-
ducted (see Methods and Discussion). In addition, we
conducted MR analysis using only one SNP at a time
and obtained similar results to those obtained when
using both SNPs (Supplementary Table 3, available as
Supplementary data at IJE online), further suggesting
our SNPs are valid IVs (see Discussion). For MMA%
and iAs%, there was evidence that fully-adjusted ob-
servational estimates (model 2) and MR estimates
were different (P¼ 0.09 and 0.02, respectively), but
not for DMA% (P¼ 0.97).
SNP-Arsenic interaction
In SNP-arsenic interaction analyses, there was sug-
gestive evidence that the individual effects of rs9527
and rs11191527 on skin lesion risk were stronger
among individuals with higher exposure, measured
as arsenic in drinking water (Table 3). When infor-
mation on these SNPs was combined into ‘high’,
‘intermediate’ and ‘low’ genetically-defined categories
of arsenic methylation capacity, there was strong
evidence that the association between SNP-based
methylation capacity and skin lesions risk was stron-
ger among individuals with higher exposure, as mea-
sured by interaction on the additive scale (synergy
index¼ 1.37, CI: 1.11, 1.62; RERI¼ 0.39, CI: 0.00,
0.79), consistent with the hypothesis that individuals
with higher arsenic metabolism capacity have lower
Table 2 Participant characteristics for all skin lesion cases
and controls with genetic data
Characteristics n (%)
Skin lesion
casesa (%) Controlsb (%)
n 5340 2483 2857
Sex
Male 2580 (48.3) 1450 (58.4) 1130 (39.6)
Female 2760 (51.7) 1033 (41.6) 1727 (60.4)
Age (yr)
430 1348 (25.2) 345 (13.9) 1003 (35.1)
31–39 1273 (23.8) 514 (20.6) 759 (26.6)
40–48 1413 (26.5) 756 (30.5) 657 (23.0)
549 1306 (24.5) 868 (35.0) 438 (15.3)
BMI (kg/m2)c
<17.56 1324 (24.9) 621 (25.1) 703 (24.8)
17.56–19.29 1333 (25.1) 608 (24.6) 725 (25.6)
19.30–21.69 1322 (24.9) 603 (24.3) 719 (25.4)
421.69 1331 (25.1) 645 (26.0) 686 (24.2)
Cigarette smoking
Current 1575 (29.5) 799 (32.2) 776 (27.2)
Former 453 (8.5) 285 (11.5) 168 (5.8)
Never 3312 (62.0) 1399 (56.4) 1913 (67.0)
Urinary arsenicc [creatinine adjusted] (mg/g)
<90 1324 (25.0) 686 (27.6) 638 (22.5)
91–177 1327 (25.0) 522 (21.0) 805 (28.4)
178–344 1321 (25.0) 521 (21.0) 800 (28.3)
5345 1322 (25.0) 733 (29.4) 589 (20.8)
Data available for a subsample of participantsd
Water arsenicd(mg/l)
n 3316 493 2823
47.00 841 (25.4) 71 (14.4) 770 (27.3)
7.01–45.25 818 (24.7) 97 (19.6) 721 (25.5)
45.26–119 830 (25.0) 138 (28.0) 692 (24.5)
5120 827 (24.9) 187 (38.0) 640 (22.7)
aCases were selected from HEALS and BEST.
bControls were selected from HEALS.
cBMI and urinary arsenic measures have <1% missing data.
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Figure 4 Associations for 10q24.32 SNPs and arsenic spe-
cies percentages in relation to skin lesion risk. Estimates for
SNPs were generated in multivariate logistic regression
models that included sex, age categories and both SNPs
coded additively (2483 cases and 2857 controls).
Observational estimates for arsenic species percentages were
generated using logistic regression and cross-sectional data
on HEALS participants with arsenic metabolite and skin
lesion status data, measured at baseline (632 cases and 4036
controls). Model 1 included adjustments for age and sex,
and model 2 included additional adjustments for smoking
and body mass index. Observational ORs correspond to a
one standard deviation increase in the metabolite. For the
Mendelian randomization estimates, first-stage regressions
were estimated using 2060 HEALS participants with arsenic
metabolite data and SNP data (rs9527 and rs11191527),
adjusting for age, sex, smoking, body mass index and
genotyping stage. F-statistics were 45, 38 and 17 for DMA%,
MMA% and iAs%, respectively. The second-stage logistic
regression models were fit using data on 2483 cases and
2857 controls with SNP data, adjusting for the same cov-
ariates included in the first-stage regression. MRORs cor-
respond to a one standard deviation change in the arsenic
species percentage
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arsenic toxicity risk. Consistent with this interaction,
we also demonstrate that the observational associ-
ation between arsenic methylation capacity and skin
lesion risk is stronger among individuals with higher
exposure levels (Supplementary Table 4, available as
Supplementary data at IJE online). Interestingly, the
effect of rs11191527 on methylation capacity appears
to depend on arsenic exposure status, whereas the
effect of rs9527 does not appear to vary substantially
across exposure strata (Supplementary Table 5, avail-
able as Supplementary data at IJE online). Thus, even
in the low exposure group (<16 mg/l), we observe an
association between rs9527 and DMA%. However, this
is not entirely unexpected, as the effects of 10q24.32
variants on arsenic methylation capacity have been
observed in prior studies of individuals with low ex-
posure.38 Our low exposure group includes very few
truly unexposed participants.
Discussion
In this work, we have used a MR approach to provide
strong evidence that arsenic methylation capacity (as
measured by either DMA%, MMA% or iAs%) is caus-
ally related to risk for arsenic toxicity (as measured by
arsenical skin lesions). We estimate that one standard
deviation increase in urinary DMA% (7–8 percent-
age points) results in an approximately 10% decrease
in the odds of skin lesions. In contrast, one standard
deviation increase in MMA% and iAs% would result
in 20% and 25% increases in the odds of skin lesions,
respectively. We also show that arsenic has a weaker
association with skin lesion risk among individuals
with high methylation capacity genotypes, consistent
with our MR results. The effect of rs11191527 on ar-
senic methylation capacity may vary by arsenic expos-
ure, so these estimates represent the average
treatment effect across all levels of arsenic exposure.
Several observational studies have reported that
increased methylation capacity is inversely associated
with arsenic toxicity,17–21 but none have used an MR
approach. The key advantage of MR in this context is
that MR estimates are not susceptible to biases stem-
ming from unmeasured confounding. It is possible
that a wide array of unmeasured (or poorly mea-
sured) lifestyle and host factors (e.g. nutrition, adi-
posity) influence both one’s capacity to methylate
arsenic and the effectiveness of host defence against
arsenic toxicity and skin lesion development, inducing
a non-causal association between methylation cap-
acity and skin lesion status. Under the assumption
that the 10q42.32SNPs used in this work are valid
IVs, we can interpret association estimates derived
from MR as causal effects. Consequently, interven-
tions that increase arsenic methylation capacity are
very likely to reduce arsenic toxicity. Several micronu-
trients related to one-carbon metabolism have been
proposed as potential modulators of arsenic metabol-
ism,39 including folate. Randomized trials have
provided strong evidence that folate supplementation
increases arsenic methylation capacity among individ-
uals with low plasma folate.40,41
This work builds on our prior work16 on this topic in
two ways. First, we have increased the sample size of
our prior SNP association study of arsenic metabol-
ites, and we can now show that only two association
signals for arsenic methylation capacity are observed
in the 10q24.32 region, and these two signals are
observed regardless of which metabolite measure is
used to represent arsenic methylation capacity. Thus,
we can use the same IVs for each arsenic methylation
phenotype. Second, by expanding the sample size of
individuals with both SNP and skin lesion data, we
now have the statistical power to conduct MR ana-
lyses that convincingly show that methylation cap-
acity is causally related to skin lesions risk, with
both SNPs providing consistent evidence.
Whereas the identity of the causal variant in the
10q24.32 region remain unknown, it is likely that
they affect the function of AS3MT, a gene with a
clear role in arsenic metabolism. However, other
genes in this region have also been suggested as
having potential roles arsenic methylation capacity
(such as C10orf32, CNNM2, NT5C2 and USMG5).42
Our group16 and others42 have shown that metabo-
lism-associated variants may influence local gene ex-
pression, a potential mechanism by which these
variants could influence arsenic methylation capacity.
The validity of our MR approach relies on the as-
sumption that our two SNPs are not related to skin
lesion risk independently of the methylation capacity
phenotype.24,25 Although this assumption cannot be
proven, its validity is supported by several observa-
tions. First, the magnitude and direction of the
SNPs’ associations with arsenic methylation capacity
and skin lesion risk are consistent, with rs11191527
having a weaker associaitons than rs9527 for both
phenotypes. Thus, our two SNPs produce similar
effect estimates when analysed in separate two-stage
models, taking into account the size of the confidence
intervals and the different effect sizes for our two
SNPs (Supplementary Table 3, available as
Supplementary data at IJE online). If one of the IVs
were invalid, these estimates would be expected to be
different.43 Second, there is clear biological plausibil-
ity for SNPs near AS3MT to have effects that are spe-
cific to arsenic methylation capacity, supporting the
validity of the IV assumptions.
In addition to the advantages of MR for isolating
causal relationships, 10q24.32 variants also capture
the effect of arsenic methylation capacity over a
large portion of the life course. The association be-
tween 10q24.32 variants and arsenic methylation cap-
acity is present for all age groups in our data, i.e. from
18 to 70 years of age; thus, its association with skin
lesion risk may reflect the cumulative effects of a life-
time of low (or high) methylation capacity. Urinary
metabolite percentages, on the other hand, may vary
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over time due to changes in factors such as arsenic
exposure or nutritional status, and may not consist-
ently reflect an individual’s long-term average cap-
acity to methylate arsenic.
Our MR analysis is limited by the fact that we only
have metabolite data for a subset of 2060 genotyped
HEALS cohort participants, which includes very few
cases (n¼ 67). However, because this is a randomly
selected sub-cohort (most of whom were free of skin
lesions at the time of measurement), the association
estimates obtained (Figure 3) represent the associ-
ations present in the population and are appropriate
for predicting arsenic metabolite percentages in larger
samples of cases and controls. Simulated data from
our group show that these subsample estimators are
unbiased when IVs are strong (F 410). We are also
limited by the fact that urinary arsenic metabolites
percentages are a proxy for the true underlying con-
struct of interest, arsenic methylation capacity.
Whereas urinary metabolites percentages are a well-
established measure of methylation capacity, these
percentages may be influenced by arsenic exposure18
and perhaps additional unmeasured factors that con-
tribute to measurement error. However, one advan-
tage of MR is that classical measurement error
in the risk factor does not result in bias or substan-
tial reductions in power.33 Power for detecting
arsenic-SNP interaction was limited by the fact that
we had prospective arsenic exposure data for only 493
genotyped cases and 2823 controls (from HEALS).
This lack of prospective exposure data for cases from
BEST prohibited us from performing IV analyses that
were stratified by arsenic exposure.
Ideally, the genetic factors used as IVs should be
identified in an independent dataset, as the associ-
ation estimates SNPs identified in a genome-wide
association study may be biased away from the null
(i.e. winner’s curse),44 potentially biasing the MR
estimate. However, because 10q24.32 variants are
well-established as determinants of arsenic metabol-
ism across several populations,23 our SNP selection
can be viewed as a regional association scan. Thus,
this potential bias is likely much less than is expected
for a genome-wide search. However, to protect
against this potential bias, we used a cross-validation
procedure (described in the Supplementary Methods,
available as Supplementary data at IJE online) to
show that we arrive at the same conclusion when
using independent datasets for IV discovery and
MR analysis (Supplementary Table 2, available as
Supplementary data at IJE online). This cross-
validation procedure was possible for DMA% and
MMA%, but not for iAs%, as the associations between
10q24.32 SNPs and iAs% were too weak to be
Table 3 Odds ratios and 95% confidence intervals for the association between AS3MT SNPs and skin lesion status (493
cases and 2823 controls) stratified by arsenic exposure (measured in drinking water)
Water arsenic
tertiles (mg/l) AS3MT genotype
Multiplicative




GG GA or AA
0.1–16 1.00 (Ref) 0.85 (0.44, 1.63) 0.06 0.45 (0.09, 0.82) 1.93 (0.60, 3.26)
17–87 1.00 (Ref) 1.08 (0.64, 1.82)
488 1.00 (Ref) 1.69 (1.12, 2.56)
rs11191527
GG GA or AA
0.1–16 1.00 (Ref) 1.14 (0.67, 1.92) 0.56 0.19 (0.49, 0.11) 0.69 (0.32, 1.07)
17–87 1.00 (Ref) 0.65 (0.43, 1.00)
488 1.00 (Ref) 0.85 (0.60, 1.22)
SNP-based arsenic methylation capacity
High Intermediate Low
0.1–16 1.00 (Ref) 1.01 (0.56, 1.83) 0.63 (0.23, 1.74) 0.13 0.39 (0.00, 0.79) 1.37 (1.11, 1.62)
17–87 1.00 (Ref) 1.45 (0.91, 2.30) 1.73 (0.84, 3.56)
488 1.00 (Ref) 1.31 (0.86, 1.99) 1.85 (1.00, 3.42)
OR, odds ratio; RERI, relative excess risk for interaction; SNP, single nucleotide polymorphism.
aInteraction analyses are adjusted for both SNPs, age and sex
In the absence of additive interaction, the RERI and the synergy index have values of 0 and 1, respectively.
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consistently detected when using only half of the
first-stage sample.
The variants used for MR in this work may not be
the best predictors of methylation capacity in other
populations. Variation in this region has been linked
to methylation capacity in several populations,23 but
the causal genetic variation underlying the 10q24.32
association signals remains unknown. Due to differ-
ences in linkage disequilibrium patterns and allele
frequencies across populations, and potential differ-
ences in the underlying causal variation, future stu-
dies should consider the possibility that other
10q24.32 SNPs may be stronger predictors of arsenic
methylation capacity than the SNPs described here. In
addition, the effects of 10q24.32 variants on arsenic
methylation capacity may vary by exposure status
(Supplementary Table 5, available as Supplementary
data at IJE online). Our results suggest that the asso-
ciation between rs11191527 and DMA% is weak or
absent among individuals with low exposure
(<16 mg/l), indicating that this variant may not be a
strong IV for methylation capacity in populations with
low exposure. Additional research on this potential
SNP-arsenic interaction is needed, and researchers
considering using 10q24.32 variants for MR should
consider the implications of such an interaction for
power and interpretation of results.
In summary, we have used MR to provide strong
evidence that arsenic metabolism efficiency has a
causal role in arsenic toxicity. We further demonstrate
this causal relationship by showing that the effects of
metabolism-related variants are stronger among indi-
viduals with high arsenic exposure. The MR methods
demonstrated here represent a powerful approach for
making causal inferences about the effects of arsenic
and arsenic metabolism on health. This approach may
be valuable for studying health conditions where the
role of arsenic is less clear, such as diabetes,45 cardio-
vascular conditions,8 non-malignant respiratory ill-
nesses46 and neurological diseases,10,11 even when
prospective data on arsenic exposure are not available.
Developing interventions that increase arsenic methy-
lation capacity are very likely to reduce the impact of
arsenic exposure on health.
Supplementary Data
Supplementary data are available at IJE online.
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KEY MESSAGES
 Epidemiological studies suggest that arsenic metabolism efficiency is inversely associated with risk for
arsenical skin lesions, presumably due to enhanced excretion of arsenic metabolites.
 Genetic variants in the 10q24.32 region are known to influence arsenic metabolism efficiency, and
these SNPs can be used to assess the causal relationship between metabolism efficiency and arsenic
toxicities using a Mendelian randomization approach.
 Using data on two 10q24.32 SNPs in an arsenic-exposed Bangladeshi cohort, we demonstrate that the
association between arsenic metabolism efficiency and arsenical skin lesions is very likely to be
causal.
 We demonstrate evidence of additive interaction between 10q24.32 genotype and arsenic exposure in
relation to skin lesion risk, providing additional support for this causal relationship.
 Developing interventions that increase arsenic metabolism efficiency are very likely to reduce the
impact of arsenic exposure on health.
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